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Renal expression of vascular endothelial growth factor in lupus nephritis in 
the pediatric age group 
 
INTRODUCTION 
Systemic lupus erythematosus (SLE) is an 
autoimmune disease characterized by acute and 
chronic inflammation of various tissues of the body. 
The antibodies and accompanying cells of 
inflammation can affect tissues anywhere in the 
body. Lupus has the potential to affect a variety of 
areas. SLE most often harms the skin, heart, lungs, 
kidneys, joints and /or nervous system. The course 
of the disease is unpredictable with periods of 
illness (called flares) alternating with remission1. 
Kidney disease is one of the commonest and the 
most serious manifestation of SLE. Despite 
improvement in the medical care of SLE in the past 
two decades the prognosis of lupus nephritis 
remains unsatisfactory. Up to 25% of patients still 
develop end stage renal failure 10 years after the 
onset of renal disease2. 
Renal biopsy is the gold standard for providing 
information on the histological classes of lupus 
nephritis and the relative degree of activity and 
chronicity in the glomeruli2. There are different 
tissue markers that have been associated with 
histological classes or renal functions deterioration 
in lupus nephritis. Intra-renal vascular endothelial 
growth factor mRNA expression predicts the 
deterioration of renal functions3. Vascular 
endothelial growth factor (VEGF) has been shown 
to stabilize kidney functions in animal model of 
thrombotic microangiopathy4. The protective 
actions were principally mediated through 
preserved glomerular and peritubular capillary 
structures. This may help to preserve glomerular 
filtration rate by maintaining glomerular capillary 
filtration surface area as well as preventing 
tubulointerstitial fibrosis5. Hence patients with 
proliferative LN who had decreased intra-renal 
VEGF expression are at risk for a rapid decline of 
renal functions at the time of renal flare. The 
combination of renal pathology such as class III/ IV 
LN and reduced VEGF expression could predict 
poor renal survival6. VEGF plays a crucial role in 
the preservation of renal functions and may also 
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serve as a useful biomarker in monitoring the 
progression of lupus nephritis7. 
With this as a background, we were simulated to 
investigate VEGF expression in the kidney in 
relation to the renal histopathological findings in a 
trial to correlate its expression with activity and 




This cross sectional study comprised 15 patients 
suffering from lupus nephritis and ten renal biopsy 
specimens from patients with polycystic kidney 
disease or solitary renal cyst were included as 
control specimens. Patients with lupus nephritis 
were enrolled consecutively from the Pediatric 
Allergy and Immunology Unit, Children's Hospital, 
Ain Shams University, Cairo, Egypt.  
The patients were fulfilling at least four of the 
revised classification criteria for SLE of the 
American College of Rheumatology "ACR"8. LN 
was diagnosed and biopsy proven according to the 
revised classification of WHO criteria of LN9. 
Hypertension was diagnosed according to the 
percentiles of blood pressure10.  
Patients with diabetes mellitus, nephrectomy, 
cyclosporine therapy or cystic kidney diseases were 
excluded from the study.  
Detailed history taking with special emphasis on 
age at onset of SLE, duration of disease and organ 
involvement was considered. The treatment 
modalities in terms of steroids dose, type and 
dosage of the immunosuppressive drugs received 
were recorded. The cumulative steroid dose was 
calculated. All forms of corticosteroids were 
converted to equivalent dose of prednisone11. 
Global disease activity was assessed by the SLE 
disease activity index (SLEDAI)12, and the British 
Isles Lupus Assessment Group (BILAG)-2004 renal 
score was used to assess the degree of renal 
involvement13-15. The Systemic Lupus International 
Collaborating Clinics/American College of 
Rheumatology (SLICC/ACR) Damage Index was 
used to assess renal damage16. 
An informed consent was obtained from the 
parents or care givers of subjects before enrollment. 
The study protocol was approved by the ethics’ 
committee of the department of pediatrics, Ain 
shams University, Cairo. 
Study Measurements 
The SLE patients were subjected to complete blood 
counting (CBC) using Coulter counter (COULTER 
MAXMUG-HL-CCI), erythrocyte sedimentation 
rate (ESR) measurement by Westergren method, 
complement 3 (C3) estimation by nephelometry 
(minineph TM, AD 200, 6326, United kingdom), and 
anti DNA measurement by indirect 
immunofluorescent microscopy (IMMCO 
Diagnostics, USA). Twenty four hours urinary 
protein quantification was performed by the 
turbidimetric method (Stanbio Laboratory Inc., San 
Antonio, TX, USA). The serum and urinary 
creatinine concentrations were measured by a 
modified rate Jaffe method 17. Serum creatinine and 
creatinine clearance assessment was carried out on 
Synchron CX7 autoanalyzer (Beckman Instruments, 
Brea, California USA). 
 
Blood collection and processing  
Five ml of venous blood were withdrawn 
aseptically into a sterile disposable syringe from 
every patient. Two ml of sample were collected in 
EDTA treated tubes for CBC and 1.5 ml of sample 
was collected in citrate tube for measuring ESR. 
The remaining part of sample was collected in plain 
tubes to be clotted and centrifuged. The yielding 
serum was used for detection of the required 
immunological markers and kidney functions.  
 
Renal biopsies 
Paraffin section already frozen and kept in 
pathology laboratory hospital was taken for 13 
patients and all control specimens while the 
remaining 2 were taken fresh specimens for 
histological analysis. Paraffin sections were cut at 4 
microns thick and subjected to routine 
haematoxylin and eosin staining and 
immunohistochemical staining for VEGF. 
Immunohistochemical staining 
Paraffin sections were fixed on poly-L-lysine 
coated slides, dried overnight in a 60C oven. Then 
they were deparaffinized and dehydrated. The slides 
were treated in microwave oven in ready to use 
antigen retrieval citrate buffer for 10 minutes, then 
sections were left to cool at room temperature for 
20 minutes. Slides were stuck to cover plates using 
PBS pH 7.6 and placed in sequenza center for 
immunostaining. Endogenous peroxidase activity 
was blocked by adding 2-3 drops of hydrogen 
peroxide blocking serum for 5 minutes at room 
temperature. Then sections were rinsed well with 
PBS for 5 minutes. Two drops of protein blocking 
serum were added for 10 minutes. No rinse after 
this step. The primary antibody was applied by 
adding 3 drops to each section [VEGF: A 
monoclonal mouse antibody (labvision, catalog No: 
#MS-353-R7) supplied as 1m1 of ready to use 
antibody 1] and incubated for 2 hours at room 
temperature, followed by rinsing in PBS pH 7.6. 
The secondary antibody was applied by adding 2 
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drops of biotinylated secondary antibody to each 
section a supersensitive immunodetection system 
(Bigenex, catalog No. AD 000-SL) for 30 minutes 
at room temperature. Slides were then rinsed in 
PBS pH 7.6. Two drops of peroxidase labeled 
streptavidin were added for 20 minutes at room 
temperature, then rinsing with PBS pH 7.6. Slides 
were incubated for 10 minutes with substrate 
chromogen (DAB) mixture. Slides were then rinsed 
with distilled water. Slides were immersed in Harris 
Haematoxylin for 3 seconds, rinsed in tap water, 
dehydrated in absolute alcohol. Lastly, slides were 
cleared in xylene and mounted by Canada Balsam 
then covered by glass cover. 
Sections of breast carcinoma were regarded as 
positive controls for CD31. They were stained in 
each run to judge the effectiveness of the technique. 
Negative control slides, were processed as the 
previous immunostaining procedure, but the 
primary antibody was omitted from the steps, and 
PBS was used instead. 
The hematoxylin & eosin stained slides were 
examined and scored for activity and chronicity 
indices. For VEGF stained slides, VEGF was 
expressed on podocytes and capillary endothelial 
cells of glomerulus and tubular epithelial cells 18. 
The intensity of immunostaining was scored as 0 
(no staining), 1+ (mild staining), 2+ (moderate 
staining), +3 (strong staining)19. 
 
Statistical Methods 
Statistical analysis was performed using Statistical 
Package for Social Sciences, Version 17.0 (SPSS, 
Inc., Chicago, III, USA) for Windows.  Continuous 
variables were expressed as mean values ± standard 
deviation (SD) or median (range) as appropriate. 
Rates and proportions were calculated for 
categorical data. For categorical variables, 
differences were analyzed with 2 (chi square) test 
and Fisher’s exact test when appropriate while 
analysis of these data before and after treatment was 
done using McNemar test. 
Kolmogorov-Smirnov test of normality was 
done to assess normality of continues variables 
before starting the analysis. Differences among 
continuous variables with normal distribution 
before and after treatment were analyzed by paired t 
test or Wilcoxon signed rank test for non-
parametric data. p value of <0.05 was considered 
statistically significant.  
 
RESULTS 
The SLE patients were 12 females and 3 males. 
Their age at disease onset ranged from 5 to 13 years 
with a mean ± SD of 9.8 ± 1.9 years. LN was 
diagnosed and biopsy proven according to the 
revised classification of WHO criteria of LN9. 
Seven patients (46.7 %) suffered from class III LN, 
five suffered from class II LN (33.3%), two 
(13.3%) suffered from class IV LN and one patient 
suffered from LN class V (6.7 %). 
Seven patients (46.7%) showed mild 
expression of VEGF in their renal biopsies, 5 
(33.3%) showed moderate while three (20%) had 
strong expression of the marker (fig.1). On the 











Figure 1. Frequency of VEGF expression among 
the studied patients. 
 
Among our patients with class II LN, only 1 
(20%) patient showed mild expression of VEGF, 3 
(60%) showed moderate expression while the last 1 
(20%) showed strong marker expression. The 
corresponding frequencies in class III LN were 3 
(43%), 2 (28.5) and 2 (28.5%) respectively. As 
regards class IV and V LN, all (100%) of our 
subjects had mild renal expression of VEGF (fig.2).  
Patients with mild VEGF expression had 
comparable age at diagnosis to those with 
moderate–strong expression, (p=1.000). Similarly, 
female predominance was observed in both groups 
with comparable frequency (p= 0.536).  
At diagnosis, patients with mild VEGF 
expression had comparable serum levels of anti-
dsDNA and C3 to patients with moderate or strong 
VEGF expression. However, the median value of 
anti DNA in the mild group was found to be nearly 
triple that of the moderate or strong groups (604 vs 
213 Iu/ml). At enrolment, subjects with 
moderate/strong VEGF expression had significantly 
higher C3 levels as compared to those with mild 
VEGF expression. However, anti DNA levels were 
comparable in both groups. 
Renal expression of VEGF failed to show a 
significant impact on renal function tests (serum 
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creatinine and creatinine clearance). The 24 hours 
urinary protein concentration tended to be higher in 
patients with mild VEGF expression as compared to 
patients with moderate or severe expression (1.5 vs 
0.5 gm/day); the difference, however, did not reach 
statistical significance. Similarly, renal expression 
of VEGF did not correlate significantly with renal 
function test results in patients with mild versus 
moderate or strong levels of expression.  
VEGF expression did not significantly influence 
the SLEDAI and renal BILAG scores of the studied 
patients at diagnosis. However, the median value of 
SLEDAI was found to be higher in patients with 
mild expression of VEGF. 
No significant relation was detected between the 
type or cumulative dose of corticosteroid and/or 
immunosuppressive (cyclophosphamide and 
azathioprine) therapy in patients with mild VEGF 
expression as compared to those with moderate or 
strong levels of expression. 
VEGF expression did not significantly affect 
activity and chronicity indices of the studied 
patients where both groups had comparable activity 
and chronicity indices. However, mild VEGF 
expression showed a higher activity score 
suggesting that a high activity index may associate 
decreased VEGF mRNA expression (table 1).  
Renal expression of VEGF showed a significant 
positive correlation with serum creatinine and the 
level of C3 while the 24 hours urinary proteins’ 
concentration was negatively correlated to the 
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expression Test value 
P 
value No % No % 
Normal 1 20 4 80 Fisher 
= 
2.143 
0.182 Activity 6 60 4 40 
Mod: Moderate, P> 0.05: non-significant, No: number, %: percentage. No 









Figure (3): Marked expression of VEGF in the glomeruli (white arrow) and tubular epithelial cells (black 





Figure (4): VEGF expression was decreased in the glomeruli and tubules of kidneys of patients with lupus 




Figure (5): VEGF protein was absent in glomeruli and markedly reduced in the tubules of kidney of 
patients with lupus nephritis class IV (VEGF, X400). 
 
 




VEGF plays a crucial role in preservation of renal 
functions and may also serve as a useful biomarker 
in monitoring the progression of LN 7. Intra renal 
VEGF mRNA expression predicts the deterioration 
of renal functions3. 
In our series, renal expression of VEGF was 
mild in about 47% of subjects and moderate in 33% 
(both together represent 80% of the studied sample) 
while only 20% of the SLE subjects studied had 
strong levels of expression which could have been 
considered a favorable marker. 
The integrity of the glomerular and peri-tubular 
capillaries is vital for renal functions. Progressive 
capillary loss, with obliteration of the 
microvasculature, frequently accompanies fibrosis, 
which is a characteristic feature of progressive renal 
disease. Progression of glomerulopathy is due to 
loss of glomerular integrity. Vascular endothelial 
growth factor (VEGF) promotes survival, 
proliferation, and differentiation of glomerular 
endothelial cells. The protective actions were 
principally mediated through preservation of 
glomerular and peritubular capillary structures20.  
All of our control specimens (100%) had strong 
expression of the marker as VEGF is known to have 
an angiogenic role in the pathogenesis of cystic 
kidney disease and is involved in the development 
of the pericystic circulation which may be 
necessary for cyst cells to grow21.  
A previous study 3 that investigated biopsy 
specimens from 35 adult patients (age 31+ 1.27 
years) with class III: IV LN (ISN/RPS 
categorization) reported that in a lupus mouse 
model as well as in LN patients, renal expression of 
VEGF was decreased and associated with a worse 
prognosis due to rapid decline of renal functions as 
compared with the control patients. The authors 
suggested that VEGF may serve as a molecular 
marker of renal damage and may be a predictive 
factor for short term loss of kidney functions in 
patients with LN. Similarly, Thacker and associates 
22 revealed that the immunohistochemistry of renal 
biopsies from patients with LN had down regulation 
of VEGF and decreased glomerular and blood 
vessel capillary density compared with controls. 
We used specimens from known patients with 
cystic kidney disease to control our results and all 
of them showed strong expression of renal VEGF. 
This was in agreement with Yoshida and 
associates23 who reported that VEGF protein 
expression was increased in the inner strips of the 
outer medulla where cystic alterations were 
prominent. A relevant study identified increased 
angiogenesis in and around the cyst walls of 14 
patients with autosomal dominant polycystic kidney 
disease (ADPKD). In addition VEGF expression 
was increased in the epithelial cells of cysts and in 
some capillaries surrounding the cysts and some 
glomeruli21.  
All subjects with class IV/V LN had mild 
expression of renal VEGF as compared to 20% and 
43% of those with class II and III respectively 
suggesting the decline of this marker with LN 
severity. This agrees with the results of a relevant 
study on 35 adult patients with class III or IV LN 
(ISN/RPS categorization) that reported lower levels 
of intra renal VEGF expression as compared to 10 
donor kidneys sampled at the time of allograft 
reperfusion. On the contrary, Frieriand associates19 
found no correlation between LN class severity and 
intensity of staining for VEGF expression. 
However, most of their patients were of the 
proliferative LN and other classes were not evenly 
expressed. Another study reported that VEGF was 
increased in plasma and renal tissue of patients with 
LN and a moderate degree of renal failure and 
assumed that overexpression of this angiogenic 
factor could be related to endothelial repair in this 
instance24. 
In our series, level of renal VEGF expression did 
not vary with the age at onset of SLE. The same 
conclusion was previously reported19.  Also we did 
not find a specific gender predilection for VEGF 
expression, where both males and females had 
comparable levels of expression and again this was 
previously concluded from a relevant study3.  
Although the serum anti-ds DNA levels did not 
vary significantly with the level VEGF expression 
in our series, the median value of anti-ds DNA in 
subjects with mild VEGF expression was nearly 
triple that of the moderate to strong group at 
diagnosis. Also, serum C3 level at enrollment was 
significantly lower in patients with mild VEGF 
expression as compared to those with 
moderate/strong expression. This may relate VEGF 
expression with the immune alternations in SLE. 
The conclusions are however limited by the sample 
size. Binding of Anti-DNA antibodies from lupus 
patients to proximal tubulo-epithelial cells leads to 
rapid internalization and triggers an inflammatory 
response characterized by increased synthesis of 
interleukin-6 and tumor necrosis factor. This 
inflammatory response in epithelial cells is 
accompanied by decreased VEGF synthesis25. 
Our patients with mild VEGF expression were 
comparable to those with moderate and severe 
VEGF expression in terms of renal function testing 
at presentation. However, renal VEGF levels 
showed a positive linear correlation to the serum 
creatinine and C3 concentrations. Also, the 24 hour 
urinary protein levels both at diagnosis and 
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enrollment were found to be higher in patients with 
mild VEGF expression as compared to the 
moderate to strong group and showed a significant 
negative linear correlation with the renal expression 
of the marker (p= 0.012). This might suggest that 
VEGF expression is related to severity of nephrosis. 
Reduction in renal VEGF could contribute to 
endothelial cell injury causing capillary rarefaction 
and leading to tubular atrophy, interstitial fibrosis 
and ultimately proteinuria26 
In a trial to evaluate the effect of VEGF on 
global disease activity and specific organ 
involvement, SLEDAI, BILAG and SLICC/ACR 
were plotted for all patients at the time of diagnosis 
as well as at enrollment. VEGF renal expression did 
not significantly influence the SLEDAI or BILAG 
scores of our SLE patients. However the median 
SLEDAI value tended to be higher in the group 
with mild renal expression of VEGF. Moreover, 
SLICC/ACR was found to be 0 in all of our SLE 
patients. This observation could be attributed to the 
small sample size or the uneven distribution of the 
classes of LN in our sample. VEGF expression did 
not significantly affect activity and chronicity 
indices of the studied patients where both groups 
had comparable activity and chronicity indices. 
However, mild VEGF expression showed a higher 
activity score suggesting that a high activity index 
may be associated with decreased VEGF mRNA 
expression. 
Avihingsanon and colleagues3 found that 53% of 
his patients with low VEGF expression but none of 
the patients with high levels experienced loss of 
their renal functions within 12 months.  They also 
reported that there was an inverse relationship 
between intra-renal VEGF and histological activity 
indices as higher activity indices were associated 
with decreased VEGF mRNA expression. Samples 
with activity score > 3 of total 24 expressed lower 
VEGF expression. 
We did not find any significant relation between 
the type or cumulative dose of immunosuppressive 
therapy received (azathioprine and cyclo-
phosphamide) and the level of renal VEGF 
expression. The variation of patients' characteristics 
and immunosuppressive treatments may be 
considered confounding factors. 
In conclusion, VEGF showed mild/moderate 
expression in the majority of our pediatric SLE 
patients especially those with class IV and V lupus 
nephritis. Patients with lower grades of renal 
involvement tended to have higher levels of VEGF 
expression. This might link higher levels of VEGF 
expression to proliferative LN. The deleterious 
effect of decreased VEGF expression could not be 
significantly highlighted among our sample. 
However, the significant positive correlation 
between VEGF expression and the serum C3 
probably supports its link to the inflammatory 
consequences of SLE. The small sample size is 
indeed a limiting factor in the analysis. 
Further longitudinal studies on a wider scale are 
needed to verify the exact pathogenetic relation 
between VEGF renal expression and proliferative 
LN (ISN/ RPS class III or IV). This marker may 
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